Thread: Positive Phase 2/3 results for Extended Release Amantadine
View Single Post
Old 06-18-2013, 06:31 PM
Tupelo3 Tupelo3 is offline
Member
  
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default Positive Phase 2/3 results for Extended Release Amantadine
Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating Scale (UDysRS). ADS-5102 is Adamas' investigational extended-release formulation of amantadine intended for once-nightly administration that is being studied for the treatment of LID in Parkinson’s disease (PD) patients.

http://bit.ly/11N09Fl
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Stand Tall (06-19-2013)